NSCLC without driver gene mutation
Conditions
Interventions
Case series:Apatinib monotherapy
Sponsors
Chongqing Fuling Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Histopathologically confirmed NSCLC; 2. Correlation detection showed no driving gene mutation; 3. Progress after second-line standard chemotherapy (RECIST evaluation); 4. Aged 18 years old or above, male or female; 5. ECOG PS: 0-2 points; 6. Estimated survival time = 12 weeks; 7. The main organ function levels meet the following criteria: 1) Blood routine examination criteria should be consistent with: ANC=1.5×10^9/L, PLT=80×10^9/L, Hb=90g/L (no blood transfusion and blood products within 14 days, no correction by G-CSF and other hematopoietic stimuli) ); 2) Biochemical examination should meet the following criteria: TBIL<1.5×ULN, ALT, AST<2.5×ULN, ALT, AST can be <5×ULN, BUN and Cr=1×ULN or endogenous creatinine clearance = 50ml/min (Cockcroft-Gault formula); 8. Women of childbearing age must have taken reliable contraceptive measures or have a pregnancy test (serum or urine) within 7 days prior to enrollment and the results are negative and willing to use appropriate during the trial and 8 weeks after the last administration of the test drug. Method of contraception. 9.Subjects voluntarily participated in this study, signed informed consent, followed up with good compliance.
Exclusion criteria
Exclusion criteria: 1. Symptomatic brain metastasis, cancerous meningitis (patients with brain metastasis who have completed treatment and stable symptoms 21 days before enrollment can be enrolled, but need to be confirmed by brain MRI, CT or venography to have no cerebral hemorrhage symptoms ); 2. Patients with central squamous cell carcinoma confirmed by histopathology or cytological examination; 3. People with high blood pressure who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg); 4. Arrhythmia with grade II or higher myocardial ischemia or myocardial infarction, poor control; 5. A variety of factors affecting oral medications (such as inability to swallow, chronic diarrhea and intestinal obstruction, significantly affecting the use and absorption of drugs); 6. In the past 6 months, there was a history of gastrointestinal bleeding or a clear tendency of gastrointestinal bleeding, such as esophageal varices with bleeding risk, focal active ulcer, occult blood in stool (++) could not be included in the group; 7. Bleeding tendency or undergoing thrombolytic or anticoagulant therapy; 8.Patients with central nervous system metastasis or known brain metastases; 9. Urine routine indicates urinary protein = ++, or confirmed 24-hour urine protein = 1.0 g; 10. Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures; 11. Combined HIV-infected patients; 12. The investigator determines other conditions that may affect the conduct of the clinical study and the outcome of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Countries
China
Contacts
Public ContactZhou Qi
Chongqing Fuling Central Hospital
Outcome results
None listed